Wandercraft raises $75M for acceleration of AI-powered humanoid robotics and exoskeletons

TravelingThe manufacturer of self-balancing robot mobility systems has provided $ 75 million to accelerate AI-powered robotics.

This capital inflows comes during rapid growth, global visibility and product update in clinical, consumer and industrial robotics.

Serial D Round Renault Group, BPifrance, European Investment Bank, Teampact enterprises and the leadership of the Quadrant came with great contributions.

The new financing will help the traveler to move to the next stage of the latest growth: in early 2026, the world’s first self-balancing personal exoskeleton; Clinical adoption of the rehabilitation system of the flange ship, Atalante X; and Calvin-40, develop and place its humanoid robot.

“The speed we get in the last few years is emergency,” Matthieu Masselin, Wandercraft CEO, in a statement. “We have expanded in the world, starting Pivotal clinical tests, read our commercial structure, personal ecoskeleton, and allow our significant partnership, rehabilitation, home environment and commercial mission in factory floors.”

News Wandercraft’s Renault GROUP is out of the post of traveler, where the car manufacturer is now a strategic partnership with minority shareholders and travelers. Partnership Renault Group’s industry expertise increases the production of travelers’ exosks and industrial robots. Renault is the first commercial partner and client called Calvin-40 for a total of 40 days.

Calvin-40 is an industrial grade robot designed for physical demanding tasks – Renault factories are set up for production within 40 weeks. The first humanoid robot developed by a European company, the rapid development of Calvin-40s, the existing leader Robotics of Wandercraft, fast development and NVIDIA, was possible using their VLA (visual language model) and the Jetson AI calculation platform. The partnership with Renault is the basis for the valuable scale scale of the eve and a wider calvin humanoid family.

Looking in front of the dial, D funding will be accelerated:

• In home and open environments, private use of private exoskeleton.
• Growth and support for Atalante X is a new stage.
• Calvin-40 and wider Calvin Humanoid family industry development and dissemination.

Today’s news raised the company’s $ 45 million C. Rour, which is 45 million dollars, led by the quadrant management, which led the rulings of the quadrant management, which led the US-raising trade expansion. Other participants around D LBO France, mutuelles effects – Xange, Cemag Invest, Martagon Capital and AG2R La Mardelles includes the effects of Loboelles managed by LA Mondiale.

Wandercraft comes from selflessness to restore independence, which allows you to move upright without emergency, self-equilibrium, seizure, capture silent robot systems or rides.

Technology is equipped with AI and has been tested with billions of simulations and ten million real world steps.

Conclusion, growing list of industry and clinical achievements: Clinical innovation equipped by AI; Exoskeleton received the first FDA clearance for the rehabilitation of Atalante X for the stroke; Cleaning a second Fda in less than a year, then expand the use of US hospitals and clinics; The self-balanced individual has launched the first clinical test of Ekzoskeleto, and prepared for those who are violating Eve’s serious mobility; Kessler Foundation, Villa Beretta Rehabilitation Innovation Institute and Vivantes Clinical and Schön Clinic and Schön Clinic and Schön Clinic, were placed in more than 100 hospitals and rehabilitation centers, including the Villa Beretta Rehabilitation Institute.

Rated travel in more than 20 clinical research; Key findings are accompanied by the perception of meaningful developments in the walking speed, balance, independence and postural control, often reduced pain, spasticity and growing muscle power. And this, 2500 people with disabilities, so far allow more than 14 million steps to the day, once again let the freedom of movement again.

The company has also expanded the possibility of rehabilitation in New York. The company offers regular eczoskeleton walking sessions for people with a walking center, stroke, strokes, MS, Parkinson’s disease and SCI, “walking in New York.

The enterprise sits in New York, as well as in the treatment of a healthcare innovation camp in New York, where the US headquarters are located. The company intends to establish a center as the first regional center for the beginning of the expected US initialization in 2026.

Product update and recognition

Travelers symbolize a new global standard in Mobility Technology in 2024, in 2024, in the Olympic and Paralympic Torch. In March, NVIDIA, NVIDIA, NVIDIA GTC conference demonstrated the NVIDIA and their annual technological conference. NVIDIA, Autonomous, Al-Al-NVIDTIA was recognized to use the most modern technologies and physical AI to provide free walks.

Wandercraft invites individual ecoskeleton to learn more about the ongoing clinical trials for Eve. The study appreciates the use of the real world, paying attention to the action, endurance and integration in daily life. A completely or older or more than 18 years older (in T6 or above, above T6) can participate or provide – physically, physically can be a companion to support. To ask or apply, email clinallyTrials@wandercraft.health. The company is hiring.

Wandercraft is a robotechnical company to recover, restore mobility and expanding what is possible through systems operating AI. Founded in 2012, Wandercraft expands the world’s first self-balancing, Atalante X, which is used in four continents to help people with disabilities. There are more than 30 patents.